BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall under COINS Act.
As companies grapple with how to best compete with — or voice concerns over — China’s growing biotech prowess, crafting a political strategy has become one of …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
PhRMA and BIO mobilize against a wave of anti-China biotech bills in Congress as lawmakers move to curb US dealmaking with China.
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill…
China's ascent is forcing U.S. biotech companies and investors to pick a side: Is it an ally or an existential threat?
China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.
Chinese drug makers are increasingly relying on overseas licensing deals to reach global markets amid growing geopolitical…
Bigger, fewer, tougher: the new era of China-US biotech partnerships
[Bio USA] Korea biotech under pressure from China's rapid rise
China closing in but US leads in biotech quality and commercial reach: survey
HHS, responding to China’s rise, moves to fast-track early drug research
